Annual Report

The report describes Kaken's 2017 consolidated performance, with net sales of ¥101,479 million and operating income of ¥30,707 million. It highlights the launch of Regroth, South Korean licensing of Clenafin, and co-promotions of Desalex. Its social-responsibility section reports companywide environmental activities and 4,152 tons of waste produced at the Shizuoka Factory, with sludge and residual materials used for composting, etc.